Nebula Research & Development LLC Xenon Pharmaceuticals Inc. Call Options Transaction History
Nebula Research & Development LLC
- $836 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding XENE
# of Institutions
212Shares Held
70.2MCall Options Held
88.3KPut Options Held
28.8K-
Avoro Capital Advisors LLC New York, NY5.67MShares$233 Million3.36% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.6MShares$189 Million1.77% of portfolio
-
Wellington Management Group LLP Boston, MA3.84MShares$158 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.71MShares$111 Million3.02% of portfolio
-
Commodore Capital LP New York, NY2.7MShares$111 Million9.03% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.56B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...